Although strategies to neutralize the effect of CD96 are not as advanced as those developed for TIGIT, these studies undeniably demonstrate that the DNAM-1/TIGIT/CD96 axis and CD155 immunoregulation represent promising targetable immunotherapeutic strategies for cancer treatment [77,78]. This evidence concerns the gene CD96 and cancer.